Metoprolol Succinate
Product Images NDC 71335-2644

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Metoprolol Succinate (NDC 71335-2644). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Figure001)

This text presents information related to a study (MERIT-HF) comparing the effects of Wetoprolol Succinate Extended-Release Tablets against a placebo on total mortality or all-cause hospitalization. The study results are provided for various subgroups based on factors such as heart failure etiology, sex, race, previous medical conditions like myocardial infarction, diabetes mellitus, and hypertension, as well as heart rate categories. The study aimed to assess the impact of Wetoprolol Succinate Extended-Release Tablets in these different subgroups on outcomes related to heart failure.*

FDA Label Image

Label (Lbl713352644)

Each film-coated extended-release tablet contains 190 mg of Metoprolol Succinate, equivalent to Metoprolol Tartrate 200 mg. Metoprolol Succinate ER tablets should be stored at 20° to 25°C (68° to 77°F) and should be kept out of reach of children. Patients should follow the pharmacist's instructions and refer to the package inserts for more information. These tablets are dispensed in a tight container as per USP guidelines and are manufactured by Visum Pharmaceutical Co., Ltd. at Burbank, CA, USA.*

FDA Label Image

Structure (Structure001)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.